Schuth Alexander O. - 17 Jan 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
COFO and Secretary
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
17 Jan 2023
Net transactions value
-$242,539
Form type
4
Filing time
19 Jan 2023, 16:09:36 UTC
Previous filing
09 Jan 2023
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $52,800 +10,000 +2% $5.28* 507,173 17 Jan 2023 See footnote F1, F2
transaction DNLI Common Stock Sale $291,934 -9,886 -1.9% $29.53 497,287 17 Jan 2023 See footnote F2, F3, F4
transaction DNLI Common Stock Sale $3,405 -114 -0.02% $29.87 497,173 17 Jan 2023 See footnote F2, F3
holding DNLI Common Stock 142,328 17 Jan 2023 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -10,000 -9.2% $0.000000 98,937 17 Jan 2023 Common Stock 10,000 $5.28 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercised shares were issued to the Schuth Family Trust.
F2 The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
F3 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.87 to $29.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 Includes 130,692 RSUs.
F6 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.